Recent Press Releases

Mylan Launches Generic Combivir(R)

Mylan Launches Generic Combivir(R) Product strengthens growing antiretroviral franchise in the U.S. PITTSBURGH, Oct. 3, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced the U.S. launch...

GSK appoints Mr Urs Rohner to its Board as a Non-Executive Director

GSK appoints Mr Urs Rohner to its Board as a Non-Executive Director GlaxoSmithKline plc (LSE: GSK) today announced the appointment of Mr Urs Rohner to its Board as a Non-Executive Director, effective...

LEO Pharma Inc. Announced New Taclonex® (calcipotriene and betamethasone dipropionate) Topical Suspension, 0.005%/0.064% Indication for Treatment of Scalp Plaque Psoriasis in Pediatric Patients Ages 12-17

LEO Pharma Inc. Announced New Taclonex® (calcipotriene and betamethasone dipropionate) Topical Suspension, 0.005%/0.064% Indication for Treatment of Scalp Plaque Psoriasis in Pediatric Patients...

Salix Pharmaceuticals and Cosmo Technologies Announce Termination of Merger Agreement

RALEIGH, N.C. & LAINATE, Italy, Oct 03, 2014 (BUSINESS WIRE) -- Salix Pharmaceuticals, Ltd. ("Salix") SLXP, +5.37% and Cosmo Pharmaceuticals S.p.A. ("Cosmo") (six:COPN) today...

Mylan Increases Third Quarter and Full Year 2014 Adjusted Diluted EPS Guidance Range

Mylan Increases Third Quarter and Full Year 2014 Adjusted Diluted EPS Guidance Range Third Quarter 2014 Financial Results Conference Call to be Held on Oct. 30, 2014 PITTSBURGH, Oct. 3, 2014...

US HER2-Positive Breast Cancer Treatment Market to More than Treble in Value by 2023, says GlobalData

US HER2-Positive Breast Cancer Treatment Market to More than Treble in Value by 2023, says GlobalData LONDON, UK (GlobalData), 2 October 2014 - The US treatment market for human epidermal growth...

Distribution changes on cancer drugs

Beginning October 1, 2014, Avastin® (bevacizumab), Herceptin® (trastuzumab) and Rituxan® (rituximab) will only be available to hospitals and clinics through authorized specialty...

AbbVie Demonstrates Commitment to Continued Research in Hepatitis C with Investigational Data from Clinical Program Being Presented at The Liver Meeting®

AbbVie Demonstrates Commitment to Continued Research in Hepatitis C with Investigational Data from Clinical Program Being Presented at The Liver Meeting® Data from 25 accepted abstracts include...

Zogenix Submits Modified Formulation of Zohydro(R) ER With Potential Abuse Deterrent Properties for FDA Review

Zogenix Submits Modified Formulation of Zohydro(R) ER With Potential Abuse Deterrent Properties for FDA Review SAN DIEGO, Oct 01, 2014 (GLOBE NEWSWIRE via COMTEX) -- Zogenix, Inc. ZGNX, +1.74% a...

Merck Completes Sale of Consumer Care Business to Bayer AG for $14.2 Billion

Merck Completes Sale of Consumer Care Business to Bayer AG for $14.2 Billion Worldwide Collaboration to Market and Develop Portfolio of Soluble Guanylate Cyclase (sGC) Modulators Commences Wednesday,...

The Lancet Publishes Two Phase 3 Studies Showing Cholesterol-Lowering Medication Evolocumab Significantly Reduced LDL Cholesterol In Patients With Serious Genetic Disorders That Cause High Cholesterol

Data From Phase 3 RUTHERFORD-2 Study Show Evolocumab Significantly Reduced Mean LDL-C by 59-66 Percent Compared to Placebo in Patients With Heterozygous Familial Hypercholesterolemia

Legal Settlement, Data Presentation, Welfare Initiatives, Acquisition Talks, and Study Results - Research Reports on Shire, Merck, Medtronic, Salix and Johnson & Johnson

Editor Note: For more information about this release, please scroll to bottom.

NEW YORK, October 1, 2014

Abbott Hosts Conference Call for Third-Quarter Earnings

ABBOTT PARK, Ill., Oct.

Amgen Announces Moderate-To-Severe Plaque Psoriasis Data To Be Presented At The 23rd Congress Of The European Academy Of Dermatology And Venereology

Featured Presentations Highlight Data From Approved and Investigational Agents Across Amgen's Dermatology Portfolio

THOUSAND OAKS, Calif.

Portola Pharmaceuticals Announces Phase 3 ANNEXA(TM)-A Study of Andexanet Alfa and Eliquis (Apixaban) Met Primary and Secondary Endpoints With High Statistical Significance

Detailed Data Showing Andexanet Alfa Significantly Reversed Anticoagulation Activity of Factor Xa Inhibitor Eliquis to be Featured at American Heart Association's "Clinical Science: Special...

Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA

LAVAL, Quebec, Sep. 30, 2014 (Canada NewsWire via COMTEX) -- Valeant Pharmaceuticals International, Inc. today announced that the company's Bridgewater, New Jersey location received a Warning...

GE Healthcare to Collaborate with GlaxoSmithKline on Commercial Oncology Testing

GE Healthcare to Collaborate with GlaxoSmithKline on Commercial Oncology Testing ALISO VIEJO, Calif., Sep 30, 2014 (BUSINESS WIRE) -- GE Healthcare today announced an agreement between its affiliate,...